<DOC>
	<DOCNO>NCT00001446</DOCNO>
	<brief_summary>This phase II study design evaluate potential clinical efficacy thalidomide patient hormone-refractory prostate cancer . An important aspect study characterize pharmacokinetics thalidomide , well make correlation degree angiogenesis occur patient activity thalidomide .</brief_summary>
	<brief_title>A Randomized Phase II Study Oral Thalidomide Patients With Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description>This phase II study design evaluate potential clinical efficacy thalidomide patient hormone-refractory prostate cancer . Patients randomize two different treatment arm ( low dose versus high dose ) . An important aspect study characterize pharmacokinetics thalidomide , well make correlation degree angiogenesis occur patient activity thalidomide . Each patient biopsiable lesion undergo pretreatment biopsy prostate ( site soft tissue disease ) repeat 2 6 month treatment . Additional information obtain change circulate level follow growth factor : bFGF , TNF , VEGF , TGFB . Neurological complication primary dose-limiting toxicity anticipate chronic thalidomide administration .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document adenocarcinoma prostate . Confirmation Clinical Center Pathology Department require . CTdefined soft tissue disease require stag prostatespecific antigen ( PSA ) less 20 ng/mL . Progressive hormonerefractory disease 1 month prior entry ( withdrawal antiandrogens ) , document least one following : 3 consecutive rising level PSA least 1 week apart . 1 measurement least 50 % great PSA nadir last therapy . New bone metastasis Tc99 bone scintigraphy . Progression measurable evaluable softtissue metastasis . Development new area disease . 25 % increase previously measure lesion . Total androgen ablation require . Testosterone castrate range . Concurrent luteinizing hormonereleasing hormone ( LHRH ) agonist require surgically castrate . No prior prostate irradiation radical prostatectomy unless biopsiable lesion available . Urgent local problem correct prior entry ( e.g. , severe bone pain , spinal cord compression , urinary flow obstruction ) . No brain metastasis . PRIOR/CONCURRENT THERAPY : Thyroid replace concurrent start study patient chemical hypothyroidism . Thyroid replace prior study patient clinical hypothyroidism . Biologic Therapy : At least 4 week since Biologic Therapy recover toxic effect . Chemotherapy : No prior suramin . At least 4 week since chemotherapy recover toxic effect . Endocrine Therapy : See Disease Characteristics . At least 4 week since hormonal therapy except LHRH agonist therapy . Radiotherapy : See Disease Characteristics . At least 4 week since radiotherapy ( 6 week since strontium ) . Surgery : See Disease Characteristics . PATIENT CHARACTERISTICS : Age : 18 . Performance status : ECOG 02 . Life expectancy : More 3 month . Hematopoietic : Absolute granulocyte count great 1,000/mm ( 3 ) . Platelet count great 75,000/mm ( 3 ) . Hemoglobin great 8.0 g/dL ( transfusion allow requirement maintain 30 day OR bleed identify treat ) . Hepatic : Bilirubin great 1.5 time normal . AST ALT less 2.5 time normal . Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 40 mL/min . Proteinuria great 2+ OR less 500 mg/24 hr ( except patient ureteral stent ) . BUN normal . Electrolytes normal . Urinalysis normal . Cardiovascular : No unstable newly diagnose angina . No myocardial infarction within 6 month . No NYHA class IIIV congestive heart failure . Pulmonary : No chronic obstructive lung disease require oxygen therapy . Neurologic : No clinically detectable peripheral neuropathy great grade 1 . No seizure within 10 year . No anticonvulsant . No requirement sedatives hypnotic . OTHER : Normal thyroid function test least 4 week prior study throughout study . No concurrent anticoagulant . No active infection . Off antibiotic least 1 week . Ureteral stent Foley catheter allow antibiotic . HIV negative . No concurrent lifethreatening illness . No concurrent malignancy . Ability travel National Institutes Health . Adequate contraception require sexually active patient partner 2 month therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>Angiogenesis</keyword>
	<keyword>Malignancy</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sedation</keyword>
</DOC>